Skip to main content

Online Only

Online Only
Oncology, Original Research
The Hidden Inferno: Burn Pit Exposure in the Military and Its Potential Links to Cancer
Claire Szewczyk
Claire Szewczyk
Read More
Online Only
FDA Approvals
FDA Accelerated the Approval of Columvi for Selected Relapsed or Refractory Large B-Cell Lymphomas
Read More
Online Only
FDA Approvals
Lynparza FDA Approved, in Combination With Abiraterone and Prednisone (or Prednisolone), for Metastatic Castration-Resistant Prostate Cancer With BRCA Mutation
Read More
Online Only
FDA Approvals
Epkinly FDA Approved for Relapsed or Refractory Diffuse Large B-Cell Lymphoma or High-Grade B-Cell Lymphoma
Read More
Online Only
FDA Approvals
Polivy Received New Indication for First-Line Treatment of Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, and High-Grade B-Cell Lymphoma
Read More
Online Only
Original Research, Practice Management, Oncology
Trends in Utilization, Prices, and Spending for Oral Medications for Breast Cancer Treatment in the US Medicaid Population, 2008-2019
Fatimah Hussain Alyami, BPharm, MS, PhD; Jeff Jianfei Guo, BPharm, PhD
Read More
Online Only
FDA Approvals
Jemperli (Dostarlimab) First Immunotherapy Approved for Recurrent or Advanced Mismatch Repair-Deficient Endometrial Cancer
Loretta Fala
Read More
Online Only
FDA Approvals
Ukoniq (Umbralisib) FDA Approved for Adults with Relapsed or Refractory Marginal-Zone Lymphoma or Follicular Lymphoman
Loretta Fala
Read More
Online Only
FDA Approvals
Tabrecta (Capmatinib) First FDA-Approved Drug for Metastatic NSCLC with MET Exon 14 Skipping Mutation
Loretta Fala
Read More
Online Only
FDA Approvals
Abecma (Idecabtagene Vicleucel) First-in-Class BCMA-Directed CAR T-Cell Therapy Approved for Relapsed or Refractory Multiple Myeloma
Loretta Fala
Read More
Page 2 of 3
Results 11 - 20 of 22